Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Antibody-Drug Conjugates: The Next Generation Of Moving Parts

Dec 27 2011

• By Alex Lash

Related Content

Back To School: Big Pharmas Test New Models For Tapping Academia

Feb 01 2011

Your First Drug's Approved and Launched...Now What?

Jul 01 2011

With Novartis, ImmunoGen Adds $45 Mil. And Another Licensor For Its Antibody-Drug Conjugate Platform

Oct 11 2010

Making The Case For Antibody-Drug Conjugates

Dec 01 2010

ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie

Feb 25 2011

Related Companies

Astellas Pharma, Inc.

Astellas Pharma, Inc.

Takeda Pharmaceutical Co. Ltd.

Roche Holding AG

Genentech, Inc.

Spirogen Ltd.

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Heidelberg Pharma AG

Heidelberg Pharma AG

Pfizer Inc.

Seagen Inc.

Takeda Pharmaceutical Co. Ltd.

ImmunoGen, Inc.

Mersana Therapeutics, Inc.

Novartis AG

Nerviano Medical Sciences SRL

National Cancer Institute

Allozyne Inc.

Catalent, Inc

Sutro Biopharma, Inc.

Cornell University

Weill Cornell Medical College

AnaptysBio, Inc.

CytomX Therapeutics, Inc.

Boehringer Ingelheim GmbH

Additional Topics

Strategy Business Strategies Clinical Trials Launches Innovation Deals Platform Technologies BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window